Scott Hessen is a Cardiology physician. OpenAlex indexes 42 publications with 690 citations (h-index 9).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
525 Jamestown St Ste 107
Philadelphia, PA 191281751
Telephone
215-482-1607Provider last certified this registry record 13 Sept 2025.
Industry payments
27 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year20255 payments
- BridgeBio Pharma, Inc.Program year20254 payments
- AstraZeneca Pharmaceuticals LPProgram year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
78.1%Beta blocker20.8%Metoprolol Succinate49%Carvedilol23%Metoprolol Tartrate13%Sotalol8%Sotalol Af3%Atenolol2%Nebivolol Hcl2%Part D<11 patientsStatin16.5%Atorvastatin Calcium59%Rosuvastatin Calcium32%Simvastatin5%Pravastatin Sodium4%Part D<11 patients+ 15 more classes in this area
Blood & clotting
17.8%Factor Xa inhibitor12.2%Eliquis64%Xarelto36%Part D≥57 patientsVitamin K antagonist3.3%Warfarin Sodium85%Jantoven15%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
3.7%Potassium supplement1.7%Potassium Chloride69%Klor-Con M2031%Part D<11 patientsSGLT2 inhibitor1.4%Jardiance62%Farxiga38%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Physician-reported reasons for not intensifying lipid-lowering therapy in patients with recent myocardial infarction
Journal of clinical lipidology
2025 - Impact of the COVID-19 pandemic on the management of risk factors in patients with stable atherosclerotic vascular disease
American Journal of Preventive Cardiology
2023 - IMPACT OF THE COVID-19 PANDEMIC ON THE MANAGEMENT OF RISK FACTORS IN PATIENTS WITH ASCVD
Journal of the American College of Cardiology
2023 - Comparison of the Four Major US Guidelines for Lipid Lowering Therapy for the Primary Prevention of ASCVD in Patients with Diabetes
Journal of clinical lipidology
2022 - Use of Guideline Directed Lipid Lowering Therapy among Patients with Diabetes without ASCVD in a Large Cardiology Practice
Journal of clinical lipidology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Scott Solomon, MD
Brigham and Women's Hospital
Eric Topol, MD
Scripps Research Institute (Scripps Research)
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”